Beta-adrenergic Receptor < Direct >

While commonly used for heart conditions, beta-blockers have been found to act as proinflammatory agents in the brain, with research in PMC7686098 indicating that they impair microglia-mediated phagocytosis of synaptic material, increasing neuroinflammation. Chronic Heart Failure (CHF): β1beta sub 1

( -ARs) are a class of G protein-coupled receptors (GPCRs) that act as key molecular targets in the sympathetic nervous system, primarily activated by catecholamines like adrenaline and noradrenaline to manage "fight or flight" responses. beta-adrenergic receptor

New studies utilize Rosetta structural modeling to map atomic-scale interactions of β1beta sub 1 β2beta sub 2 While commonly used for heart conditions, beta-blockers have

Recent, high-impact research (2023–2025) has moved beyond basic cardiovascular signaling, focusing on deep molecular insights into receptor structure, cancer metastasis, and developmental biology. 1. Advanced Structural and Functional Insights (2025) Distinct types of β1beta sub 1 β2beta sub 2 β3beta sub 3 ) are organized in specific cardiac zones. β1beta sub 1 inactive)

with specific beta-blockers, allowing for state-specific modeling (active vs. inactive). 2. Emerging Roles in Disease Pathogenesis -adrenergic signaling (specifically

-AR activation) increases cancer cell stiffness, enhancing mobility and promoting metastasis. Studies have shown that blocking ARs can attenuate lung metastasis in various cancer models.